<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To compare the effect of a fixed combination of an <z:chebi fb="67" ids="50114">oestrogen</z:chebi> (17-beta <z:chebi fb="0" ids="23965">oestradiol</z:chebi>) with a cyclical progestagen (<z:chebi fb="0" ids="7627">norethisterone</z:chebi>) on glycaemic control, plasma <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> and haemostatic factors in women with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Oral and transdermal hormone replacement therapy (HRT) were compared to no HRT treatment in 33 postmenopausal women with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, in a 12-week randomised prospective open parallel group study </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: In the 11 women who received 12 weeks of oral HRT, there was a significant fall in total cholesterol (5.9+/-1.0 (S.D.) to 4.7+/-1.0 mmol l(-1), P=0.005), <z:chebi fb="1" ids="47774">low density lipoprotein cholesterol</z:chebi> (3.44+/-0.89 to 2.77+/-0.92 mmol l(-1), P=0.005) and <z:chebi fb="0" ids="17855">triglyceride</z:chebi> values (median (range)), (2.46 (0.96-5.52) to 2.29 (1.00-3.87) mmol l(-1), P&lt;0.05) </plain></SENT>
<SENT sid="3" pm="."><plain>Oral HRT improved glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbA(1c)) (7.4+/-1.4 to 6.8+/-1.2%, P&lt; or =0.005) </plain></SENT>
<SENT sid="4" pm="."><plain>Oral HRT additionally reduced the cell <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> factor E-selectin (82+/-33 to 60+/-20 microg l(-1), P&lt;0.01) and factor VII (143+/-25 to 109+/-24% pooled plasma activity, P&lt;0.01) </plain></SENT>
<SENT sid="5" pm="."><plain>No improvement in any of these parameters, except E-selectin (65+/-19 to 58+/-18 microg l(-1), P&lt;0.01), occurred in the nine women receiving transdermal HRT, and no improvement occurred in the 13 controls randomised to no treatment </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: In women with Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, cyclical <z:chebi fb="67" ids="50114">oestrogen</z:chebi> and progestagen taken orally for 12 weeks significantly improved glycaemic control and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> concentrations </plain></SENT>
<SENT sid="7" pm="."><plain>These metabolic benefits were not apparent when a similar HRT preparation was administered transdermally </plain></SENT>
</text></document>